2-叔丁基-4-羟基-6-甲基嘧啶 | 90565-53-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-叔丁基-4-羟基-6-甲基嘧啶
• 英文名称: 4-Hydroxy-6-methyl-2-tert.butyl-pyrimidin
• 英文别名: 2-tert-butyl-4-hydroxy-6-methylpyrimidine；6-methyl-2-tert-butyl-4-hydroxypyrimidine；2-tert-butyl-6-methyl-3H-pyrimidin-4-one；2-tert-butyl-6-methylpyrimidin-4-ol；2-Tert-butyl-6-methylpyrimidin-4-ol；2-tert-butyl-4-methyl-1H-pyrimidin-6-one
• CAS: 90565-53-0
• 化学式: C₉H₁₄N₂O
• mdl: MFCD09881380
• 分子量: 166.223
• InChiKey: IBOBNSVBINATPR-UHFFFAOYSA-N

物化性质

• 沸点：
  240.7±23.0 °C(Predicted)
• 密度：
  1.05±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.555
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 储存条件：
  | 2-8°C |

反应信息

• 作为反应物：
  描述：

  2-叔丁基-4-羟基-6-甲基嘧啶 在 三氯氧磷 作用下， 生成 2-(tert-butyl)-4-chloro-6-methylpyrimidine
  参考文献：
  名称：

  Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT2A, 5-HT2C, and the serotonin transporter as a potential antidepressant

  摘要：

  Pyrimidine usually has good pharmacokinetic properties as a drug substance and considerable efforts have been devoted to develop pyrimidine derivatives into drug candidates. Arylpiperazine-containing pyrimidine 4-carboxamide derivatives were synthesized and evaluated for binding to serotonin receptors and transporter. Pyrimidine derivatives showed good antidepressant activity in FST (forced swimming test) animal model and also displayed no appreciable inhibitory activity against hERG channel blocking assay. Herein SAR studies of pyrimidine derivatives targeting serotonin receptors and transporter will be disclosed. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.09.081
• 作为产物：
  描述：

  乙酰乙酸乙酯 、 2,2-二甲基丙脒 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 生成 2-叔丁基-4-羟基-6-甲基嘧啶
  参考文献：
  名称：

  Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT2A, 5-HT2C, and the serotonin transporter as a potential antidepressant

  摘要：

  Pyrimidine usually has good pharmacokinetic properties as a drug substance and considerable efforts have been devoted to develop pyrimidine derivatives into drug candidates. Arylpiperazine-containing pyrimidine 4-carboxamide derivatives were synthesized and evaluated for binding to serotonin receptors and transporter. Pyrimidine derivatives showed good antidepressant activity in FST (forced swimming test) animal model and also displayed no appreciable inhibitory activity against hERG channel blocking assay. Herein SAR studies of pyrimidine derivatives targeting serotonin receptors and transporter will be disclosed. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.09.081

文献信息

• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES
  申请人：NOVARTIS AG

  公开号：WO2010029082A1

  公开（公告）日：2010-03-18

  The present invention relates to a compound of formula (I) (I) or a salt thereof, wherein the substituents are as defined in the description, to compositions and use of the compounds in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase.

  本发明涉及一种式（I）（I）的化合物或其盐，其中取代基如描述中所定义，以及所述化合物在治疗通过抑制磷脂酰肌醇3-激酶改善的疾病中的应用。
• CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2
  申请人：Zhang Xuqing

  公开号：US20110306592A1

  公开（公告）日：2011-12-15

  The present invention comprises compounds of Formula (I). wherein: R 1 , R 2 , X, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明包括式(I)的化合物。其中：R1、R2、X和Z如规范中所定义。该发明还包括一种预防、治疗或改善综合症、紊乱或疾病的方法，其中所述综合症、紊乱或疾病为II型糖尿病、肥胖和哮喘。该发明还包括通过给哺乳动物施用至少一种式(I)化合物的治疗有效量来抑制CCR2活性的方法。
• 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2
  申请人：Zhang Xuqing

  公开号：US20100267688A1

  公开（公告）日：2010-10-21

  The present invention comprises compounds of Formula (I). wherein: X, R 1 , R 2 , R 3 , and R 4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明包括式(I)的化合物。其中：X、R1、R2、R3和R4如规范中定义。该发明还包括一种预防、治疗或改善综合症、疾病或疾病的方法，其中所述综合症、疾病或疾病是2型糖尿病、肥胖和哮喘。该发明还包括通过给哺乳动物施用式(I)的至少一种化合物的治疗有效量来抑制CCR2活性的方法。
• Insecticidal thionophosphonates
  申请人：Bayer Aktiengesellschaft

  公开号：US04940698A1

  公开（公告）日：1990-07-10

  Insecticidal O-(6-methyl-2-alkyl-pyrimidin-4-yl) O-alkyl thionoalkanephosphonates of the formula ##STR1## in which R stands for methyl or ethyl, R.sup.1 stands for methyl or ethyl and R.sup.2 stands for isopropyl or tert-butyl.

  公式为##STR1##的杀虫O-(6-甲基-2-烷基嘧啶-4-基)O-烷基硫代烷基膦酸酯，其中R代表甲基或乙基，R.sup.1代表甲基或乙基，R.sup.2代表异丙基或叔丁基。
• 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2
  申请人：Zhang Xuqing

  公开号：US20100144695A1

  公开（公告）日：2010-06-10

  The present invention comprises compounds of Formula (I). wherein: R 1 , R 2 , R 3 , and R 4 are as defined in the specification. The invention also comprises pharmaceutical compositions comprising the compounds of formula (I) and methods of preventing, treating or ameliorating a CCR2 mediated syndrome, disorder or disease, for example, type II diabetes, obesity or asthma, by administering the compounds of formula (I).

  本发明涉及式（I）的化合物。其中：R1、R2、R3和R4如规范中所定义。该发明还涉及包含式（I）化合物的药物组合物，以及通过给予式（I）化合物来预防、治疗或改善CCR2介导的综合症、疾病或疾病的方法，例如II型糖尿病、肥胖或哮喘。